Background: The effects of radiation therapy can impact patients’ quality of life, leading to treatment interruptions and therefore sub-optimal outcomes. The main aim was to evaluate the preliminary effects of Ocoxin cream® in the prevention of radiation therapy. Methods: Fifty patients were enrolled in an observational, longitudinal, prospective, single-centre clinical trial in the Department of Radiation Therapy at the National Institute of Oncology and Radiobiology in Havana, Cuba. The Radiation Therapy Oncology Group (RTOG) toxicity criteria were used to classify the radiation therapy, and the Dermatology Life Quality Index (DLQI) instrument was used to assess quality of life. Results: Patients who met the inclusion criteria were enrolled consecutively and were treated with teletherapy using a 60Co source with 1.25 MeV energy. 70.0% of the patients were head and neck cancer patients. No grade 3 - 4 radiation therapy was reported, nor were there any interruptions in radiation treatment due to skin toxicity. Radiation therapy was observed in only 14.0% of patients, and of these, only two patients developed grade 2 toxicity. The perception of quality of life before vs. after radiation therapy remained within an average range of “no effect” (at the start of radiation therapy) to “small effect” (at the end of radiation therapy). Conclusions: This clinical study is the first report of the use of Ocoxin cream® in cancer patients and demonstrates that it is able to prevent radiation therapy and reduce the severity of toxicity of treatment with ionising radiation.
Iris B. Inguanzo-ValdésHelga Candanedo-PazoAixa Ulloa-BalmasedaOslay Cervantes-HernándezAcralis de La Cruz-GalgueraMartha Lugioyo-LugoRosa M. Ortiz-ReyesMircea Betancourt-CabezaJorge Luis Soriano-GarcíaRamón Ropero-Toirac
Objective:This study investigates the preventive and therapeutic effects of medical radiation protection spray(Bergmann)compared to triethanolamine cream in patients undergoing radiotherapy following breast cancer surgery.Methods:Ninety patients with breast cancer who received postoperative radiotherapy between July 2018 and July 2021 were randomly divided into the Bergmann treatment(experimental)group and the triethanolamine cream treatment(control)group,with 45 patients in each group.Radiodermatitis severity was assessed using the RTOG radiodermatitis grading standards.Results:The radiation dose required to develop grade I radiodermatitis was significantly higher in the experimental group compared to the control group,at(36.13±1.17 Gy)and(25.38±0.63 Gy),respectively.At a radiation dose of 30 Gy,the proportion of grade I radiodermatitis cases in the experimental group was significantly lower than in the control group(P=0.002).At radiation doses of 40 Gy and 50 Gy,the proportion of grade II radiodermatitis cases in the experimental group was also significantly lower than in the control group(P<0.001).No cases of grade III or higher radiodermatitis were observed in the experimental group,while three cases of grade III radiodermatitis occurred in the control group,although the difference was not statistically significant.No patients in the experimental group discontinued treatment due to radiodermatitis or mucosal reactions,whereas two patients in the control group interrupted treatment due to these reactions but eventually completed therapy.Conclusion:Bergmann spray effectively prevents radiodermatitis in patients undergoing radiotherapy after breast cancer surgery and is more effective than triethanolamine cream in treating skin lesions.Its ease of use improves the quality of life for patients undergoing radiotherapy and ensures successful treatment completion.Bergmann is suitable for clinical promotion and application.
Yuge RanChan LiuLanhui YuanHuibin YangLei SuKunjie WangQianqian HanXiaoxi WuHongyun Shi
